Roche's PD-L1 antibody Tecentriq in the Phase 3 clinical trial of NSCLC patients reached the primary endpoint

On March 22, Genentech, a subsidiary of Roche, announced that its PD-L1 antibody Tecentriq (atezolizumab, atelizumab) will be used for the treatment of early stage non-small cell lung cancer (NSCLC) patients in Phase 3 clinical trials.

Lung cancer is one of the leading causes of cancer deaths in the world, and NSCLC accounts for 80-85% of all lung cancers.

Tecentriq is an anti-PD-L1 monoclonal antibody that binds to the PD-L1 protein on the surface of tumor cells and tumor infiltrating immune cells.

In a randomized, multi-center, open-label phase 3 clinical study named IMpower010, NSCLC patients in stage IB-IIIA were surgically removed and treated with cisplatin, and then randomly received Tecentriq or the best supportive treatment.

Note: The original text has been deleted

Reference materials:

[1] Pivotal Phase III Study Shows Genentech's TecentriqHelped People With Early Lung Cancer Live Longer Without Their DiseaseReturning.